Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016
Published Jul 20, 2016
144 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
- The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan merger

  
Source:
Document ID
GMDHC8300IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Non Alcoholic Fatty Liver Disease (NAFLD) Overview101
Therapeutics Development112
  Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) Overview111
  Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) Comparative Analysis121
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Development by Companies132
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Investigation by Universities/Institutes151
Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Products Glance164
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
  Unknown Stage Products191
Non Alcoholic Fatty Liver Disease (NAFLD) Products under Development by Companies202
Non Alcoholic Fatty Liver Disease (NAFLD) Products under Investigation by Universities/Institutes221
Non Alcoholic Fatty Liver Disease (NAFLD) Companies Involved in Therapeutics Development2325
  Arisaph Pharmaceuticals, Inc.231
  AstraZeneca Plc241
  Betagenon AB251
  Can-Fite BioPharma Ltd.261
  Cerenis Therapeutics Holding SA271
  Conatus Pharmaceuticals Inc.281
  Corcept Therapeutics Incorporated291
  Daewoong Pharmaceutical Co., Ltd.301
  Dimerix Bioscience Pty Ltd311
  Dr. Falk Pharma GmbH321
  DURECT Corporation331
  Eternygen GmbH341
  Galmed Pharmaceuticals Ltd.351
  Huons Co., Ltd.361
  Kyorin Pharmaceutical Co., Ltd.371
  Matinas BioPharma Holdings, Inc.381
  Novartis AG391
  NovaTarg Therapeutics, Inc401
  Osel, Inc.411
  Sancilio &Company, Inc.421
  TaiwanJ Pharmaceuticals Co., Ltd.431
  TCM Biotech International Corp441
  Tobira Therapeutics, Inc.451
  Zafgen Inc.461
  Zydus Cadila Healthcare Limited471
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Assessment4812
  Assessment by Monotherapy Products481
  Assessment by Combination Products491
  Assessment by Target503
  Assessment by Mechanism of Action533
  Assessment by Route of Administration562
  Assessment by Molecule Type582
Drug Profiles6069
  (leucine + metformin hydrochloride + sildenafil citrate) Drug Profile602
  (leucine + PDE5 Inhibitor) Drug Profile621
  AC-261066 Drug Profile631
  Aramchol Drug Profile645
  ARI-3037MO Drug Profile692
  AZD-4076 Drug Profile712
  C-10 Drug Profile732
  CBM-588 Drug Profile752
  cenicriviroc mesylate Drug Profile776
  CER-209 Drug Profile831
  CF-102 Drug Profile844
  CORT-118335 Drug Profile881
  dapagliflozin propanediol Drug Profile896
  DMX-300 Drug Profile951
  Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders Drug Profile961
  DUR-928 Drug Profile972
  DWP-10292 Drug Profile991
  emricasan Drug Profile1006
  FLB-12 Drug Profile1061
  HU-002 Drug Profile1071
  KDT-501 Drug Profile1081
  MAT-8800 Drug Profile1091
  MN-002 Drug Profile1101
  naltrexone hydrochloride Drug Profile1112
  norursodeoxycholic acid Drug Profile1131
  O-304 Drug Profile1142
  oltipraz Drug Profile1161
  pradigastat sodium Drug Profile1172
  RT-200 Drug Profile1191
  RT-210 Drug Profile1201
  saroglitazar Drug Profile1212
  SC-410 Drug Profile1231
  Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease Drug Profile1241
  Small Molecules to Activate AMPK for Fatty Liver Disease Drug Profile1251
  Small Molecules to Inhibit NaCT for Metabolic Diseases Drug Profile1261
  TCM-606F Drug Profile1271
  ZGN-839 Drug Profile1281
Non Alcoholic Fatty Liver Disease (NAFLD) Dormant Projects1292
Non Alcoholic Fatty Liver Disease (NAFLD) Discontinued Products1311
Non Alcoholic Fatty Liver Disease (NAFLD) Product Development Milestones13211
  Featured News &Press Releases1321
    Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions1321
    Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China1321
    Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial1331
    May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting1331
    Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease1331
    Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study1341
    Jan 11, 2016: Can-Fite Announces Update on CF1021351
    Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-9281351
    Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment1361
    Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease1371
    Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease1381
    May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study1381
    Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH1391
    Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting1401
    Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study1412
Appendix1432
  Methodology1431
  Coverage1431
  Secondary Research1431
  Primary Research1431
  Expert Panel Validation1431
  Contact Us1431
  Disclaimer1441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Non-Alcoholic-Fatty-Liver-Disease-NAFLD-Pipeline-Review-H2-2016-2088-16263>
  
APA:
Global Markets Direct - Market Research. (2016). Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Non-Alcoholic-Fatty-Liver-Disease-NAFLD-Pipeline-Review-H2-2016-2088-16263>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.